221 related articles for article (PubMed ID: 33742299)
21. Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.
Gupta N; Reckamp KL; Camidge DR; Kleijn HJ; Ouerdani A; Bellanti F; Maringwa J; Hanley MJ; Wang S; Zhang P; Venkatakrishnan K
Clin Transl Sci; 2022 May; 15(5):1143-1154. PubMed ID: 35041775
[TBL] [Abstract][Full Text] [Related]
22. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
23. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
Hamilton G; Hochmair MJ
Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
[No Abstract] [Full Text] [Related]
25. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
[TBL] [Abstract][Full Text] [Related]
26. A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study.
Wen J; Bao S; Cai Y; Zhang B; Wang R; Wang C; Hu G
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():84-89. PubMed ID: 29032042
[TBL] [Abstract][Full Text] [Related]
27. Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Exposure-Response Analyses of Pivotal ALTA Study.
Gupta N; Wang X; Offman E; Rich B; Kerstein D; Hanley M; Diderichsen PM; Zhang P; Venkatakrishnan K
CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):718-730. PubMed ID: 33185028
[TBL] [Abstract][Full Text] [Related]
28. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
[TBL] [Abstract][Full Text] [Related]
30. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
[TBL] [Abstract][Full Text] [Related]
31. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
32. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
[TBL] [Abstract][Full Text] [Related]
33. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
34. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient.
Hochmair M; Weinlinger C; Prosch H
Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499
[TBL] [Abstract][Full Text] [Related]
35. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.
Sparidans RW; Li W; Schinkel AH; Schellens JHM; Beijnen JH
J Pharm Biomed Anal; 2018 Nov; 161():136-143. PubMed ID: 30149189
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
[TBL] [Abstract][Full Text] [Related]
37. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
38. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
Preston RA; Marbury T; Balaratnam G; Green M; Dixon S; Lehrer-Graiwer J; Washington C
J Clin Pharmacol; 2021 Apr; 61(4):493-505. PubMed ID: 33084052
[TBL] [Abstract][Full Text] [Related]
40. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
